Summary & Overview
HCPCS J1830: Interferon Beta-1b Injection, 0.25 mg
HCPCS Level II code J1830 denotes a physician-supervised injection of interferon beta-1b, 0.25 mg. This code applies when the medication is administered in a clinical setting under direct physician supervision and is not appropriate for self-administered dosing. Interferon beta-1b is used in the management of certain neurological disorders, and accurate coding is important for proper claims processing, clinical documentation, and payment adjudication.
Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical context, typical sites of service, and common billing considerations relevant to payer policies. The publication outlines benchmark and coverage topics such as payer acceptance, clinical indications implied by the drug, and contexts where physician supervision affects code use. It also highlights where input data is not available for specific items like associated taxonomies or ICD-10 diagnoses.
This summary serves clinicians, coding professionals, and revenue cycle staff seeking a practical, nationally focused briefing on HCPCS Level II code J1830 to support accurate claim submission and administrative clarity.
Billing Code Overview
HCPCS Level II code J1830 describes an injection of interferon beta-1b, 0.25 mg. The code is used when the drug is administered under the direct supervision of a physician and is not for self-administration.
-
Service type: Parenteral drug administration (physician-supervised injectable biologic)
-
Typical site of service: Physician office or other supervised outpatient setting where injectable therapies are given under direct physician supervision.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with relapsing-remitting multiple sclerosis presents to an outpatient infusion clinic for a supervised dose of interferon beta-1b. The medication is supplied as a prefilled syringe and is administered by a licensed nurse under direct physician supervision because the patient cannot self-inject reliably due to dexterity limitations and history of injection-site complications. The clinical workflow includes verification of physician order, allergy and medication reconciliation, vital signs and neurologic check, informed consent documentation, preparation and administration of J1830 per manufacturer dosing, a 30-minute post-injection observation period for acute reactions, and documentation of lot number, dose, and supervising physician. Billing is submitted to the patient’s payor after confirming medical necessity for disease-modifying therapy for multiple sclerosis and ensuring the service is reported with the appropriate HCPCS code and any applicable modifier for supervision or patient condition.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstance applies |
22 |